Aziz, Faisal
Tripolt, Norbert J.
Pferschy, Peter N.
Scharnagl, Hubert
Abdellatif, Mahmoud
Oulhaj, Abderrahim
Benedikt, Martin
Kolesnik, Ewald
von Lewinski, Dirk
Sourij, Harald
Funding for this research was provided by:
Austrian Science Fund (KLI 1155-B)
Article History
Received: 4 March 2024
Accepted: 30 March 2024
First Online: 27 April 2024
Declarations
:
: The study including patients’ consent was approved by the relevant regulatory authorities and the Ethics Committee of Medical University of Graz, Austria (EK 29–179 ex 16/17; EudraCT 2016-004591-22) and registered on ClinicalTrials.gov (NCT03087773). The EMMY trial was conducted in full conformity with the 1964 Declaration of Helsinki and all subsequent revisions, as well as in accordance with the guidelines laid down by the International Conference on Harmonization for Good Clinical Practice (ICH GCP E6 guidelines).
: Not applicable (as covered by the ethics approval).
: H.S. is on the advisory board and speaker’s bureau of by Boehringer Ingelheim, NovoNordisk, Sanofi-Aventis, Amgen, AstraZeneca, Bayer, Eli Lilly, Cancom, MSD, and Daiichi Sankyo. D.V.L. is on the advisory board and speakers’ bureau of Abiomed, AstraZeneca, Bayer, Daiichi Sankyo, Orion, Sanofi, and Servier and receives consulting fees from Recardio Inc, Bayer, TLL, Vaxxinity Inc. Other authors report no competing interests related to this study.